Kulkarni Law Firm

10/05/2026

FDA’s enforcement push on GLP-1 copies in 503A products signals a new future of pharmacy compounding? I spoke with CBS News to break down the legal implications for healthcare providers and manufacturers.
https://buff.ly/X716RCE

The FDA has warned a major compounding pharmacy that it violated federal law by making copies of blockbuster weight-loss drugs in "inordinate amounts."

10/03/2026

Shared my legal perspective with CBS News regarding the FDA's crackdown on GLP-1 drug .
While pharmacies may attempt to reframe their approaches, the regulatory window is rapidly closing.

https://cbsn.ws/4d6GAFg

The FDA has warned a major compounding pharmacy that it violated federal law by making copies of blockbuster weight-loss drugs in "inordinate amounts."

09/29/2026

Excited to be quoted by CBS News on the FDA’s latest warning letter to compounding pharmacies producing GLP-1 weight-loss drugs. As regulatory boundaries tighten, the avenue for mass compounding is definitely getting narrower.
https://buff.ly/X716RCE

The FDA has warned a major compounding pharmacy that it violated federal law by making copies of blockbuster weight-loss drugs in "inordinate amounts."

09/29/2026

Is the FDA drawing a definitive line in the sand on compounded GLP-1 medications? Read my analysis in CBS News.

09/24/2026

As a patient you want to avoid fake bodega peptides!
WIRED featured our insight on product safety, and I was quoted!!
https://bit.ly/4yVnLNM

WIRED tested samples of four types of peptides. The results show how lightly regulated the industry is, even as popularity surges.

09/22/2026

Dont go to your corner store to buy peptides!!? You really need to be told that??
We spoke to about regulatory enforcement.
https://bit.ly/4yVnLNM

WIRED tested samples of four types of peptides. The results show how lightly regulated the industry is, even as popularity surges.

09/22/2026

Gotta love it when WIRED quotes me on viral peptide testing!

Independent testing exposes unverified safety risks. What does this mean for you?

https://bit.ly/4yVnLNM

09/18/2026

Marketing compounded weight-loss treatments as "FDA-approved" or "generic Ozempic" is drawing heavy scrutiny from state AGs and advertising regulators. Medspas must re-evaluate their marketing tactics and GLP-1 sourcing to avoid severe deceptive trade practice penalties.
https://buff.ly/NqLmEk9

Owners of medspas—medical clinic/day spa hybrids that offer minimally invasive cosmetic procedures in a spa-like setting—are often fooled by their own relaxed, retail-friendly atmosphere and often believe that they exist in a regulatory gray area.

09/16/2026

Dont mix custom vitamin IV bags in a back room. You must meet sterile compounding requiring strict USP standards.

Preparing formulations outside proper cleanroom environments puts both patient safety and professional licenses on the line.

https://buff.ly/NqLmEk9

safety

Owners of medspas—medical clinic/day spa hybrids that offer minimally invasive cosmetic procedures in a spa-like setting—are often fooled by their own relaxed, retail-friendly atmosphere and often believe that they exist in a regulatory gray area.

09/15/2026

Labeling "For Research Use Only" won't shield a clinic when selling directly to patients. Avoid board suspensions, severe monetary fines, and criminal charges.

https://bit.ly/4yGrI8R
sciences

Owners of medspas—medical clinic/day spa hybrids that offer minimally invasive cosmetic procedures in a spa-like setting—are often fooled by their own relaxed, retail-friendly atmosphere and often believe that they exist in a regulatory gray area.